Senti Biosciences is expected to report a consensus revenue of $1.42 million and an EPS of -$0.33 for Q2 2026, while the stock currently trades at $2.45 compared to an $8.00 average analyst target.
Investors are primarily focused on clinical data updates and the development timeline for SENTI-202, their lead Logic Gated cell therapy candidate for AML. The market is also keenly watching for updates on the company's cash runway, which was previously projected to fund operations into early 2027. Recent momentum has been driven by progress in their Gene Circuit platform and potential partnership expansions in the oncology space.